US Gov't Takes On Predatory Publishers

The Federal Trade Commission has filed a legal complaint against the OMICS Group for allegedly engaging in deceptive practices.

Written byBob Grant
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

FLICKR, BRIAN TURNERPredatory publishers take notice: the US Federal Trade Commission (FTC) is coming for you. The FTC is taking a journal publisher, the OMICS Group, to court, alleging that the open-access operation and two of its subsidiaries misrepresent their editorial process and take advantage of academics seeking outlets for their work. The legal complaint, filed in the US District Court for the District of Nevada last week (August 25), marks the first time that the FTC has gone after so-called predatory publishers for questionable business practices, such as making up their own impact factors, charging authors exorbitant fees, and circumventing the peer-review process.

Ioana Rusu, an attorney with the FTC, told Inside Higher Ed that a rising call from academics prompted the move. “There was definitely a sense that nobody had done anything about it,” she said. “Now we’re watching.”

OMICS Group landed in hot water in 2013, when the US Department of Health and Human Services (HHS) told the publishing group to stop violating HHS trademarks by falsely claiming that OMICS papers were indexed by PubMed, PubMed Central, and other HHS databases—a claim reiterated in the FTC’s complaint.

The conference arm of OMICS’s business is also mentioned in the FTC’s complaint, with the agency claiming that the publisher often promotes conferences in which attendees or speakers are listed without these people knowing about their supposed participation.

“We ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies